"Symptom Flare Up" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transient exacerbation of symptoms of an existing disease or condition.
| Descriptor ID |
D000067251
|
| MeSH Number(s) |
C23.550.291.937.500
|
| Concept/Terms |
Symptom Flare Up- Symptom Flare Up
- Flare Up, Symptom
- Flare Ups, Symptom
- Symptom Flare Ups
- Symptom Flaring Up
- Flaring Up, Symptom
- Flaring Ups, Symptom
- Symptom Flaring Ups
- Acute Symptom Flare
- Acute Symptom Flares
- Flare, Acute Symptom
- Flares, Acute Symptom
- Symptom Flare, Acute
- Symptom Flares, Acute
- Symptom Flareup
- Flareup, Symptom
- Flareups, Symptom
- Symptom Flareups
- Symptom Flare-up
- Flare-up, Symptom
- Flare-ups, Symptom
- Symptom Flare-ups
|
Below are MeSH descriptors whose meaning is more general than "Symptom Flare Up".
Below are MeSH descriptors whose meaning is more specific than "Symptom Flare Up".
This graph shows the total number of publications written about "Symptom Flare Up" by people in this website by year, and whether "Symptom Flare Up" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Symptom Flare Up" by people in Profiles.
-
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
-
Prediction models of treatment response in lupus nephritis. Kidney Int. 2022 02; 101(2):379-389.
-
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients. Lupus Sci Med. 2021 05; 8(1).
-
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294.
-
COVID, Biologics, and Psoriasis Therapy. J Am Acad Dermatol. 2020 12; 83(6):1577-1578.
-
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 03; 71(3):451-459.
-
Optimizing outcomes of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2018 11; 24(6):606-611.
-
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in?Children With Polyarticular Forms of Juvenile Idiopathic?Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 09; 70(9):1508-1518.
-
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2018 04; 70(4):594-605.
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.